CardioComm Solutions, Inc.

EKGGF · Other OTC · USD

0,0068USD

0,00 (0,00 %)Stand 9. Nov., 21:00

Vortag 0,0068

Kennzahlen

Eröffnung
0,01
Vortag
0,0068
Tagesspanne
0,0068 – 0,01
52 Wochen
0,0046 – 0,0109
Volumen
60.000
Ø Volumen
16.778
Börsenwert
1,34 Mio. $
KGV
–
Gewinn je Aktie (TTM)
-0,00
Dividendenrendite
–
Beta
-1,3
Nächste Zahlen
26. Nov. 2026

Finanzen

CADFY 2025FY 2024FY 2023FY 2022FY 2021
Umsatz271.935526.676876.414995.814682.511
Herstellungskosten501.48718.844127.721255.42945.065
Bruttogewinn−229.550507.832748.693740.385637.446
Forschung und Entwicklung000011.144
Vertrieb und Verwaltung670.283638.169864.383734.143809.532
Operatives Ergebnis−571.898,3−261.164−115.6906242−142.059
EBITDA−543.252−127.659−44.21650.98558.648
Nettogewinn−529.056−194.576−97.326−2455283
Gewinn je Aktie (verwässert)-0,00-0,00-0,000,000,00

Bewertung

Gerade nicht verfügbar.

FY 2025FY 2024FY 2023FY 2022FY 2021
Bruttomarge−84,4 %96,4 %85,4 %74,3 %93,4 %
Operative Marge−210,3 %−49,6 %−13,2 %0,6 %−20,8 %
Nettomarge−194,6 %−36,9 %−11,1 %−0,2 %0,0 %
KGV-3,7-11,4-1,3-831,919.986,4
Kurs-Umsatz-Verhältnis7,24,10,12,18,3
Kurs-Buchwert-Verhältnis-2,8-7,8-0,2-5,0-13,4
Verschuldungsgrad-1,0-1,0-1,0-0,8-1,0
Liquidität 3. Grades0,20,30,30,40,5
Dividendenrendite0,0 %0,0 %0,0 %0,0 %0,0 %
Unternehmenswert2,6 Mio.2,37 Mio.518.424,272,33 Mio.5,99 Mio.
EV/EBITDA-4,8-18,6-11,745,7102,1
Eigenkapitalrendite76,8 %70,4 %19,3 %0,6 %−0,1 %
Kapitalrendite (ROIC)−25.451,6 %−4.950,0 %753,8 %−10,0 %−1.020,6 %
Free-Cashflow-Rendite−23,3 %−5,4 %−46,7 %2,2 %−2,2 %

Wachstum

FY 2025FY 2024FY 2023FY 2022FY 2021
Umsatz−48,4 %−39,9 %−12,0 %+45,9 %−18,2 %
Bruttogewinn−145,2 %−32,2 %+1,1 %+16,1 %−13,2 %
Operatives Ergebnis−119,0 %−125,7 %−1.953,4 %+104,4 %−2.449,2 %
Nettogewinn−171,9 %−99,9 %−3.864,4 %−967,5 %+100,4 %
Gewinn je Aktie−145,5 %−83,3 %0,0 %0,0 %+100,0 %
Freier Cashflow−293,6 %−106,2 %−226,5 %+135,9 %−627,4 %
Dividende je Aktie0,0 %0,0 %0,0 %0,0 %0,0 %

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Nächste Zahlen: 26. Nov. 2026
Aug. 2026Dez. 2025Aug. 2025Mai 2025Nov. 2024Aug. 2024Mai 2024
Gewinn je Aktie · Erwartet–––––––
Gewinn je Aktie · Tatsächlich-0,00-0,00-0,00-0,00-0,00-0,000,00
Abweichung–––––––
Umsatz · Tatsächlich64.63331.60052.87070.248103.17772.55886.205

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

–

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

–

Vergleichbare Unternehmen

Über das Unternehmen

CardioComm Solutions, Inc., established in 1989 and based in Toronto, Canada, specializes in developing advanced technological solutions for cardiac monitoring. The company delivers both sophisticated software and hardware products, as well as core laboratory reading services, specifically designed for electrocardiogram (ECG) and ambulatory arrhythmia detection systems. These comprehensive offerings cater to both the medical sector and individual consumers across the globe. At the heart of CardioComm's operations is proprietary technology that underpins the entire ECG workflow: from initial recording and seamless transmission to detailed viewing, in-depth analysis, comprehensive reporting, and secure long-term storage. This end-to-end capability is crucial for the effective screening, accurate diagnosis, and ongoing management of cardiac patients. Their unique device connectivity and ECG management platforms are integrated into diverse solutions, spanning general medical applications, consumer-grade health products, clinical research initiatives, and modern telemedicine services. The company's extensive software suite includes the Global ECG Management System (GEMS) for cardiac event monitoring, GlobalCardio 12 Lead—a web-enabled and EMR-compatible ECG device—and GEMS Lite for Windows, an electronic system for receiving ECG data. Complementary software modules further enhance their offerings, such as GEMS WIN Air for live wireless ECG monitoring, AutoAttendant to empower healthcare providers by automating routine tasks, and the GEMS HL7 Interface, which ensures compliant data exchange with other EMR systems. Additionally, GlobalCardio EMR integration facilitates the bi-directional transfer of crucial information, including patient data, reports, and related links. Beyond software, CardioComm provides a range of hardware products. These include the portable HeartCheck PEN and HeartCheck handheld ECG monitors, various Sirona telephonic and wireless event recorders, and the HeartCheck CardiBeat device. Furthermore, the company offers Application Service Provider (ASP) solutions, notably C4 ECG management services and HeartCheck SMART Monitoring. Their broader product portfolio also features GlobalCardio 3 Lead, the ECG Viewer SDK, QRS Diagnostic, and QRS 12 Lead Universal.

Führung

  • Etienne GrimaChief Executive Officer, Corporate Secretary & Director
  • Robert E. CainesChairman & Chief Financial Officer
  • Branislav VasilijevicDirector of Software Engineering
CEO
Etienne Grima
Mitarbeitende
16
Hauptsitz
Toronto, ON, CA
Sektor
Technology
Branche
Software - Application
Börsengang
26. Apr. 2010

Nachrichten

Gerade keine Nachrichten zu diesem Unternehmen.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.